

Insulins, Rapid-Acting – Overview of Drug Information Service (DIS) Presentation

The primary document used for this review was prepared by the University of Utah DIS and completed September 2008. The document includes efficacy and safety data for the following short-acting insulins for the treatment of diabetes: insulin aspart (NovoLog®—Novo Nordisk), insulin glulisine (Apidra®—Sanofi Aventis), insulin lispro (Humalog®—Eli Lilly), and regular human insulin (Humulin® R—Lilly; Novolin® R—Novo Nordisk). The review includes a list of the specific agents currently marketed in the US, along with information about delivery devices available, mixing information, and comparative pharmacodynamics.

The DIS also reviewed supplemental information submitted to us by the manufacturer of insulin aspart (NovoLog®—Novo Nordisk). The efficacy and safety data for the included agents is current and complete.

September 3, 2008.